At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Phentermine-Topiramate ER +1 moredrug
Likely dose
Phentermine-Topiramate ER 3.75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients
In Brief
A Phase 4 clinical trial evaluating Phentermine-Topiramate ER and Placebo for Obesity. Completed, enrolled 24 participants across 1 site.
Detailed Summary
Our overall goal is to determine the effect of Phentermine and Topiramate ER on gastric emptying, gastric accommodation, satiety, and satiation in obese participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedApr 2013
Primary CompletionMar 2014
TodayJul 2026
First PostedApr 17, 2013
Enrollment StartApr 1, 2013
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 13.2 years ago
Interventions
Phentermine-Topiramate ERdrug
The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
Placebodrug
Placebo pills matched the study drug in appearance for the 2 dose levels.